

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 61336

Title: Change in Neoadjuvant Chemotherapy could alter the Prognosis of Patients with Pancreatic Adenocarcinoma: a case report

Reviewer's code: 01588784

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Assistant Professor, Senior Lecturer, Surgeon

Reviewer's Country/Territory: Japan

Author's Country/Territory: Brazil

Manuscript submission date: 2020-12-02

Reviewer chosen by: Li Ma

Reviewer accepted review: 2020-12-17 10:25

Reviewer performed review: 2020-12-22 12:58

Review time: 5 Days and 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This case report demonstrated that gemcitabine plus nab-paclitaxel may be considered as one of the treatment regimens for neoadjuvant chemotherapy for locally advanced pancreatic cancer, particularly for those FOLFIRINOX was not effective. Given the well-known poor survival, researches and trials on neoadjuvant chemotherapy for pancreatic cancer has been always of great concern. However, this paper does not seem to provide sufficient information for readers, so please be advised to revise or add the following points: ABSTRACT 1) Background: First sentence can be omitted, because repeated phrases appeared in the following main text. 2) Case presentation: The paragraph only described the imaging findings, and did not mention about the treatment regimen or clinical courses. More informative presentation is desired. 3) Conclusion: Readers may confuse whether gemcitabine plus nab-paclitaxel is effective as the second line treatment or the alternative regimen for neoadjuvant treatment. MAIN TEXT Background 1) Second paragraph can be omitted and included in the Discussion. 2) Third paragraph needs references. 3) Fourth paragraph needs to clarify that chemotherapies were conducted in a neoadjuvant setting. Case presentation 1) Additional CT figures are needed for the status after FOLFIRINOX treatment. 2) Additional PET/CT figures are needed for the status after the exploratory laparotomy. 3) Did you mean frozen section for 'freezing test'?? 4) Figure 3 did not match the corresponding sentence (rather reflects the last sentence). 5) On the whole, it is not easy to understand the timeline of the treatment course. For example, the interval from the gem-nab pac treatment to the second surgery was unknown (the authors mentioned the date May 2019). Furthermore, in the last sentence 'so far' did not specify the length of disease-free survival. Discussion 1) It was well described, hopefully recent clinical trials may be added (for example, PREP-01 study; J Gastroenterol 2019 etc.)



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

References 1) Ref. 5 and 9 were duplicated. 2) Ref. 18 and 19 were duplicated.

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 61336

Title: Change in Neoadjuvant Chemotherapy could alter the Prognosis of Patients with Pancreatic Adenocarcinoma: a case report

Reviewer's code: 05244644

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Chief Doctor, Deputy Director, Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Brazil

Manuscript submission date: 2020-12-02

Reviewer chosen by: Li Ma

Reviewer accepted review: 2020-12-24 01:15

Reviewer performed review: 2020-12-24 02:28

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

The manuscript entitled “Change in Neoadjuvant Chemotherapy could alter the Prognosis of Patients with Pancreatic Adenocarcinoma: a case report” present an excellent case report.

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 61336

Title: Change in Neoadjuvant Chemotherapy could alter the Prognosis of Patients with Pancreatic Adenocarcinoma: a case report

Reviewer's code: 02507819

Position: Editorial Board

Academic degree: FRCS (Gen Surg), MBBS, MD, MNAMS

Professional title: Professor

Reviewer's Country/Territory: India

Author's Country/Territory: Brazil

Manuscript submission date: 2020-12-02

Reviewer chosen by: Li Ma

Reviewer accepted review: 2020-12-16 18:23

Reviewer performed review: 2020-12-27 10:02

Review time: 10 Days and 15 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Excellent paper. It gives a hope to patients not responding to standard FOLFIRINOX regime. I congratulate the authors.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 61336

Title: Change in Neoadjuvant Chemotherapy could alter the Prognosis of Patients with Pancreatic Adenocarcinoma: a case report

Reviewer's code: 01588784

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Assistant Professor, Senior Lecturer, Surgeon

Reviewer's Country/Territory: Japan

Author's Country/Territory: Brazil

Manuscript submission date: 2020-12-02

Reviewer chosen by: Man Liu (Part-Time Editor)

Reviewer accepted review: 2021-01-18 10:44

Reviewer performed review: 2021-01-19 02:22

Review time: 15 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Abstract 1) Please add an explanation that R0 surgical resection was performed after the GEM plus nab-pac neoadjuvant treatment. Main text 1) Treatment: Please specify the time interval from the last session of GEM plus nab-pac treatment and the second surgery. 2) Discussion: Ref 19 (Motoi et al.) describes the use of S-1 plus GEM for neoadjuvant treatment, not with FOLFIRINOX. Please indicate that FOLFIRINOX as well as other regimens have been recommended for the first treatment.